Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Diaceutics ( (GB:DXRX) ) has provided an update.
Diaceutics has secured a $5.1 million contract with a global pharmaceutical company to provide laboratory engagement services through its DXRX platform over the next 24 months. The contract, which is the second largest in the company’s history, aims to support the customer’s oncology therapy by engaging and educating pathology laboratories on HER2 testing in cancer types that previously did not require it. This deal not only demonstrates the strategic value of Diaceutics’ offerings but also has the potential to impact patient lives positively through optimized therapy options.
More about Diaceutics
Diaceutics is a technology and solutions provider specializing in the pharma and biotech industry. It offers an end-to-end commercialization solution for precision medicines through its DXRX platform, which integrates data analytics and scientific services. The company focuses on enabling pharma companies to improve patient outcomes by ensuring the right diagnostic tests and therapies are available.
YTD Price Performance: 10.46%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $127.5M
For a thorough assessment of DXRX stock, go to TipRanks’ Stock Analysis page.
